Table 2 Studies reporting IGF-I and IGFBP-3 levels in lung cancer patients and their controls Serum factors References Cases Cases

    N1 Mean(ng/ml) SD(ng/ml) N2 Mean(ng/ml) SD(ng/ml) IGF-1 [14] 93 — — 186 — —   [15] 230 123 46.43 740 127 41.62   [16] 159 158 56 297 153 54   [17] MK-2206 price 194 124 54 9351 126 57   [18] 200 137.2 52.3 400 145.5 52   [19] 167 — — 498 — — IGFBP-3 [14] 93 — — 186 — —   [15] 230 1793 487.43 740 1863 458.76   [16] 159 30700 8200 297 29400 7900   [17] 194 2780 860 9351 2990 810   [18] 200 2228 650 400 2369 640   [19] 167 — — 498 — — N1 is the number of cases, N2 is the number of controls; —, not available. For IGF-I, the results of our meta-analysis and its graphic plot are presented in Table 3 and https://www.selleckchem.com/products/bay-57-1293.html Figure 1. Figure 1 Graphic representation of the meta-analysis for IGF-I and lung cancer. The ORs and their 95% confidence intervals in the original studies are shown.. Figure 2 Funnel plot for publication bias in the analysis of IGF-I and lung cancer. Each circle indicates the logarithm of the odds ratio of lung cancer comparing the subjects in the highest category with selleckchem the lowest (vertical axis) and the standard error of logarithm of odds ratio in each study. The line in the centre indicates the summary diagnostic odds ratio.

Table 3 Individual and combined WMD, ORs and 95% CIs by IGF-I and IGFBP-3 References IGF-1 IGFBP-3   WMD(95%CI) OR(95%CI) WMD(95%CI) OR(95%CI) [14] — 0.54(0.14,2.07) — 0.90(0.28,2.85) [15] -4.00(-10.71,2.71) 0.86(0.47,1.57) -70.00(-141.14,1.14) 0.50(0.25,1.02) [16] 5.00(-5.65,15.65) 0.64(0.3,11.33) 1300.00(-259.41,2859.41) 2.35(1.13,4.92) [17] -2.00(-9.69,5.69) 1.74(1.08,2.81) -210.00(-332.13,-87.87) 0.67(0.45,1.01) [18] -8.30(-17.16,0.56) 0.76(0.39,1.49) Obatoclax Mesylate (GX15-070) -141.00(-250.77,-31.23) 0.71(0.35,1.47) [19] — 1.21(0.62,2.35) — 1.70(0.87,3.30) Totol effect -3.04(-7.10,1.02) 0.87(0.60,1.13) -112.28(-165.88,-58.68) 0.68(0.48,0.88) —, not available. We also examined the possible association of IGFBP-3 and the risk of lung cancer as presented in Table 3 and Figure 3. When we compared the highest to the lowest levels of IGFBP-3, the people in the highest strata had a 0.68(95%CI: 0.48~0.88) times higher risk of developing breast cancer. The association was statistically significant. Similarly, we also did not find any publication bias between the studies (P = 0.502; Figure 4). Figure 3 Graphic representation of the meta-analysis for IGFBP-3 and lung cancer. The ORs and their 95% confidence intervals in the original studies are shown..